{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:49:36Z","timestamp":1794005376752,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite pharmacological advances such as lenvatinib approval, therapeutic failure of hepatocellular carcinoma (HCC) remains a big challenge due to the complexity of its underlying molecular mechanisms. Neuropilin-1 (NRP1) is a co-receptor involved in several cellular processes associated to chemoresistance development. Since both the double-edged process of autophagy and hypoxia-derived response play crucial roles in the loss of therapeutic effectiveness, herein we investigated the interplay among NRP1, autophagy and hypoxia in development of lenvatinib resistance in HCC cell lines. We first analyzed NRP1 expression levels in human HCC samples from public databases, found significantly increased NRP1 expression in human HCC samples as well as its correlation with advanced tumor and metastasis stages. Among 3 HCC cell lines (HepG2, Huh-7 and Hep3B), Hep3B and Huh-7 cells showed significantly increased NRP1 expression levels and cell migration ability together with higher susceptibility to lenvatinib. We demonstrated that NRP1 gene silencing significantly enhanced the anticancer effects of lenvatinib on Hep3B and Huh-7 cells. Furthermore, lenvatinib suppressed NRP1 expression through promoting autophagy in Hep3B and Huh-7 cells; co-treatment with bafilomycin A1 attenuated the antitumor effects of lenvatinib, and NRP1 silencing prevented this loss of in vitro effectiveness of lenvatinib even in the presence of bafilomycin A1. In addition, exposure to a hypoxic microenvironment significantly decreased NRP1 expression through autophagy in Hep3B and Huh-7 cells. Under hypoxia, HIF-1\u03b1 directly modulated NRP1 expression; HIF-1\u03b1 silencing not only enhanced the anticancer effects of combined lenvatinib and hypoxia, but also prevented the loss of effectiveness caused by bafilomycin A1, highlighting the potential role of HIF-1\u03b1-derived hypoxia response in the adaptive cellular response to lenvatinib and promoting resistance acquisition by autophagy modulation. Overall, NRP1 may constitute a potential therapeutic target to prevent lenvatinib failure derived from a hypoxia-associated modulation of autophagy in advanced HCC.<\/jats:p>","DOI":"10.1038\/s41401-022-01021-2","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T08:08:49Z","timestamp":1668413329000},"page":"1066-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation"],"prefix":"10.1038","volume":"44","author":[{"given":"Paula","family":"Fern\u00e1ndez-Palanca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Payo-Seraf\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"M\u00e9ndez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Tu\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gonz\u00e1lez-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Mauriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"1021_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1021_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.","journal-title":"Nat Rev Dis Prim"},{"key":"1021_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/cancers14030621","volume":"14","author":"B Cucarull","year":"2022","unstructured":"Cucarull B, Tutusaus A, Rider P, Hern\u00e1ez-Alsina T, Cu\u00f1o C, de Frutos PG, et al. Hepatocellular carcinoma: molecular pathogenesis and therapeutic advances. Cancers (Basel). 2022;14:621.","journal-title":"Cancers (Basel)"},{"key":"1021_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2147\/JHC.S285726","volume":"8","author":"F Fornari","year":"2021","unstructured":"Fornari F, Giovannini C, Piscaglia F, Gramantieri L. Elucidating the molecular basis of sorafenib resistance in HCC: current findings and future directions. J Hepatocell Carcinoma. 2021;8:741\u201357.","journal-title":"J Hepatocell Carcinoma"},{"key":"1021_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87.","journal-title":"Signal Transduct Target Ther"},{"key":"1021_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0159-1","volume":"50","author":"C M\u00e9ndez-Blanco","year":"2018","unstructured":"M\u00e9ndez-Blanco C, Fondevila F, Garc\u00eda-Palomo A, Gonz\u00e1lez-Gallego J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50:134.","journal-title":"Exp Mol Med"},{"key":"1021_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3389\/fcell.2020.00662","volume":"8","author":"A Dumond","year":"2020","unstructured":"Dumond A, Pag\u00e8s G. Neuropilins, as relevant oncology target: Their role in the tumoral microenvironment. Front Cell Dev Biol. 2020;8:662.","journal-title":"Front Cell Dev Biol"},{"key":"1021_CR8","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/ijms20082049","volume":"20","author":"V Napolitano","year":"2019","unstructured":"Napolitano V, Tamagnone L. Neuropilins controlling cancer therapy responsiveness. Int J Mol Sci. 2019;20:2049.","journal-title":"Int J Mol Sci"},{"key":"1021_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3390\/ijms20030639","volume":"20","author":"S Niland","year":"2019","unstructured":"Niland S, Eble JA. Neuropilins in the context of tumor vasculature. Int J Mol Sci. 2019;20:639.","journal-title":"Int J Mol Sci"},{"key":"1021_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10071715","volume":"10","author":"MHR Bao","year":"2021","unstructured":"Bao MHR, Wong CCL. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells. 2021;10:1\u201318.","journal-title":"Cells"},{"key":"1021_CR11","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.3390\/cancers11121984","volume":"11","author":"C M\u00e9ndez-Blanco","year":"2019","unstructured":"M\u00e9ndez-Blanco C, Fondevila F, Fern\u00e1ndez-Palanca P, Garc\u00eda-Palomo A, van Pelt J, Verslype C, et al. Stabilization of hypoxia-inducible factors and BNIP3 promoter methylation contribute to acquired sorafenib resistance in human hepatocarcinoma cells. Cancers (Basel). 2019;11:1984.","journal-title":"Cancers (Basel)"},{"key":"1021_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09520-5","volume":"22","author":"Z Chen","year":"2022","unstructured":"Chen Z, Yuan T, Yan F, Ye S, Xie Q, Zhang B, et al. CT-707 overcomes hypoxia-mediated sorafenib resistance in hepatocellular carcinoma by inhibiting YAP signaling. BMC Cancer. 2022;22:425.","journal-title":"BMC Cancer"},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1007\/s13277-015-3068-0","volume":"36","author":"NAA Osman","year":"2015","unstructured":"Osman NAA, Abd El-Rehim DM, Kamal IM. Defective Beclin-1 and elevated hypoxia-inducible factor (HIF)-1\u03b1 expression are closely linked to tumorigenesis, differentiation, and progression of hepatocellular carcinoma. Tumor Biol. 2015;36:4293\u20139.","journal-title":"Tumor Biol"},{"key":"1021_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/ijms22010179","volume":"22","author":"CW Yun","year":"2021","unstructured":"Yun CW, Jeon J, Go G, Lee JH, Lee SH. The dual role of autophagy in cancer development and a therapeutic strategy for cancer by targeting autophagy. Int J Mol Sci. 2021;22:179.","journal-title":"Int J Mol Sci"},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/cancers11111775","volume":"11","author":"CJ Ho","year":"2019","unstructured":"Ho CJ, Gorski SM. Molecular mechanisms underlying autophagy-mediated treatment resistance in cancer. Cancers (Basel). 2019;11:1775.","journal-title":"Cancers (Basel)"},{"key":"1021_CR16","first-page":"1329","volume":"9","author":"S Yang","year":"2019","unstructured":"Yang S, Yang L, Li X, Li B, Li Y, Zhang X, et al. New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies. Am J Cancer Res. 2019;9:1329\u201353.","journal-title":"Am J Cancer Res"},{"key":"1021_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03553-7","volume":"12","author":"Y Wu","year":"2021","unstructured":"Wu Y, Zhang J, Li Q. Autophagy, an accomplice or antagonist of drug resistance in HCC? Cell Death Dis. 2021;12:266.","journal-title":"Cell Death Dis"},{"key":"1021_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1126\/science.aan2507","volume":"357","author":"M Uhlen","year":"2017","unstructured":"Uhlen M, Zhang C, Lee S, Sj\u00f6stedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:660.","journal-title":"Science"},{"key":"1021_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649\u201358.","journal-title":"Neoplasia"},{"key":"1021_CR20","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013W102.","journal-title":"Nucleic Acids Res"},{"key":"1021_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138.","journal-title":"Nat Biotechnol"},{"key":"1021_CR22","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets \u2013 Update. Nucleic Acids Res. 2013;41:D991\u2013995.","journal-title":"Nucleic Acids Res"},{"key":"1021_CR23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1053\/j.gastro.2011.12.039","volume":"142","author":"S Roessler","year":"2012","unstructured":"Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 2012;142:957\u201366.","journal-title":"Gastroenterology"},{"key":"1021_CR24","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1242\/jcs.195057","volume":"129","author":"MP Thom\u00e9","year":"2016","unstructured":"Thom\u00e9 MP, Filippi-Chiela EC, Villodre ES, Migliavaca CB, Onzi GR, Felipe KB, et al. Ratiometric analysis of acridine orange staining in the study of acidic organelles and autophagy. J Cell Sci. 2016;129:4622\u201332.","journal-title":"J Cell Sci"},{"key":"1021_CR25","doi-asserted-by":"publisher","first-page":"11770","DOI":"10.3390\/ijms222111770","volume":"22","author":"F Fondevila","year":"2021","unstructured":"Fondevila F, M\u00e9ndez-Blanco C, Fern\u00e1ndez-Palanca P, Payo-Seraf\u00edn T, van Pelt J, Verslype C, et al. Autophagy-related chemoprotection against sorafenib in human hepatocarcinoma: Role of FOXO3 upregulation and modulation by regorafenib. Int J Mol Sci. 2021;22:11770.","journal-title":"Int J Mol Sci"},{"key":"1021_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"1021_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/bjc.2012.563","volume":"108","author":"S Carbajo-Pescador","year":"2013","unstructured":"Carbajo-Pescador S, Steinmetz C, Kashyap A, Lorenz S, Mauriz JL, Heise M, et al. Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells. Br J Cancer. 2013;108:442\u20139.","journal-title":"Br J Cancer"},{"key":"1021_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/7651_2019_259","volume":"2109","author":"S Martinotti","year":"2020","unstructured":"Martinotti S, Ranzato E. Scratch wound healing assay. Methods Mol Biol. 2020;2109:225\u20139.","journal-title":"Methods Mol Biol"},{"key":"1021_CR29","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.4251\/wjgo.v13.i12.2076","volume":"13","author":"T Sho","year":"2021","unstructured":"Sho T, Morikawa K, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, et al. Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. World J Gastrointest Oncol. 2021;13:2076\u201387.","journal-title":"World J Gastrointest Oncol"},{"key":"1021_CR30","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1021\/jm901755g","volume":"53","author":"A Jarvis","year":"2010","unstructured":"Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010;53:2215\u201326.","journal-title":"J Med Chem"},{"key":"1021_CR31","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.7150\/jca.56123","volume":"12","author":"L Cong","year":"2021","unstructured":"Cong L, Yi J, Qiu S, Wang R, Jin S, Jiang R, et al. Effect of EG00229 on radiation resistance of lung adenocarcinoma cells. J Cancer. 2021;12:6105\u201317.","journal-title":"J Cancer"},{"key":"1021_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13046-021-01832-x","volume":"40","author":"A Dumond","year":"2021","unstructured":"Dumond A, Brachet E, Durivault J, Vial V, Puszko AK, Lepelletier Y, et al. Neuropilin 1 and neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma. J Exp Clin Cancer Res. 2021;40:33.","journal-title":"J Exp Clin Cancer Res"},{"key":"1021_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12253-015-0003-z","volume":"22","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu P, Jiang Y, Dou X, Yan J, Ma C, et al. High expression of neuropilin-1 associates with unfavorable clinicopathological features in hepatocellular carcinoma. Pathol Oncol Res. 2016;22:367\u201375.","journal-title":"Pathol Oncol Res"},{"key":"1021_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cca.2018.06.046","volume":"485","author":"J Lin","year":"2018","unstructured":"Lin J, Zhang Y, Wu J, Li L, Chen N, Ni P, et al. Neuropilin 1 (NRP1) is a novel tumor marker in hepatocellular carcinoma. Clin Chim Acta. 2018;485:158\u201365.","journal-title":"Clin Chim Acta"},{"key":"1021_CR35","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.21873\/anticanres.13802","volume":"39","author":"S Ogasawara","year":"2019","unstructured":"Ogasawara S, Mihara Y, Kondo R, Kusano H, Akiba J, Yano H. Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo. Anticancer Res. 2019;39:5943\u201382.","journal-title":"Anticancer Res"},{"key":"1021_CR36","doi-asserted-by":"publisher","first-page":"109573","DOI":"10.1016\/j.cellsig.2020.109573","volume":"70","author":"JL Roberts","year":"2020","unstructured":"Roberts JL, Poklepovic A, Booth L, Dent P. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells. Cell Signal. 2020;70:109573.","journal-title":"Cell Signal"},{"key":"1021_CR37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2020.11.008","volume":"74","author":"M Arechederra","year":"2021","unstructured":"Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol. 2021;74:893\u2013906.","journal-title":"J Hepatol"},{"key":"1021_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-020-01029-3","volume":"14","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Huang C, Lu L, Yu K, Zhao J, Chen M, et al. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. J Hematol Oncol. 2021;14:16.","journal-title":"J Hematol Oncol"},{"key":"1021_CR39","doi-asserted-by":"publisher","first-page":"118642","DOI":"10.1016\/j.lfs.2020.118642","volume":"264","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Song J, Zhang D, Wu F, Tu J, Ji J. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Life Sci. 2021;264:118642.","journal-title":"Life Sci"},{"key":"1021_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2368-5","volume":"11","author":"X Ma","year":"2020","unstructured":"Ma X, Qiu Y, Sun Y, Zhu L, Zhao Y, Li T, et al. NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway. Cell Death Dis. 2020;11:174.","journal-title":"Cell Death Dis"},{"key":"1021_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13046-022-02306-4","volume":"41","author":"D Li","year":"2022","unstructured":"Li D, Yao Y, Rao Y, Huang X, Wei L, You Z, et al. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma. J Exp Clin Cancer Res. 2022;41:116.","journal-title":"J Exp Clin Cancer Res"},{"key":"1021_CR42","doi-asserted-by":"publisher","first-page":"5556306","DOI":"10.1155\/2021\/5556306","volume":"2021","author":"W Cao","year":"2021","unstructured":"Cao W, Liu X, Zhang Y, Li A, Xie Y, Zhou S, et al. BEZ235 increases the sensitivity of hepatocellular carcinoma to sorafenib by inhibiting PI3K\/AKT\/mTOR and inducing autophagy. Biomed Res Int. 2021;2021:5556306.","journal-title":"Biomed Res Int"},{"key":"1021_CR43","doi-asserted-by":"publisher","unstructured":"Feng Y, Zhang D, He G, Liu Y, Zhao Y, Ren X, et al. AZD4547 and the alleviation of hepatoma cell sorafenib resistance via the promotion of autophagy. Anticancer Agents Med Chem 2022. https:\/\/doi.org\/10.2174\/1871520622666220425124419.","DOI":"10.2174\/1871520622666220425124419"},{"key":"1021_CR44","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.canlet.2016.09.033","volume":"383","author":"G Liu","year":"2016","unstructured":"Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, et al. Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett. 2016;383:171\u201382.","journal-title":"Cancer Lett"},{"key":"1021_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02508-y","volume":"22","author":"J Xu","year":"2022","unstructured":"Xu J, Su Z, Cheng X, Hu S, Wang W, Zou T, et al. High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma. Cancer Cell Int. 2022;22:115.","journal-title":"Cancer Cell Int"},{"key":"1021_CR46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4149\/neo_2020_200914N982","volume":"68","author":"X Li","year":"2021","unstructured":"Li X, Zhou Y, Hu J, Bai Z, Meng W, Zhang L, et al. Loss of neuropilin1 inhibits liver cancer stem cells population and blocks metastasis in hepatocellular carcinoma via epithelial-mesenchymal transition. Neoplasma. 2021;68:325\u201333.","journal-title":"Neoplasma"},{"key":"1021_CR47","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3892\/etm.2012.803","volume":"5","author":"J Xu","year":"2013","unstructured":"Xu J, Xia J. NRP-1 silencing suppresses hepatocellular carcinoma cell growth in vitro and in vivo. Exp Ther Med. 2013;5:150\u20134.","journal-title":"Exp Ther Med"},{"key":"1021_CR48","first-page":"1350","volume":"52","author":"C Tomida","year":"2018","unstructured":"Tomida C, Yamagishi N, Nagano H, Uchida T, Ohno A, Hirasaka K, et al. VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1\/cMet in colon cancer cells. Int J Oncol. 2018;52:1350\u201362.","journal-title":"Int J Oncol"},{"key":"1021_CR49","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2152\/jmi.64.250","volume":"64","author":"C Tomida","year":"2017","unstructured":"Tomida C, Yamagishi N, Nagano H, Uchida T, Ohno A, Hirasaka K, et al. Antiangiogenic agent sunitinib induces epithelial to mesenchymal transition and accelerates motility of colorectal cancer cells. J Med Invest. 2017;64:250\u20134.","journal-title":"J Med Invest"},{"key":"1021_CR50","doi-asserted-by":"publisher","first-page":"28074","DOI":"10.1074\/jbc.M804203200","volume":"283","author":"D Bae","year":"2008","unstructured":"Bae D, Lu S, Taglienti CA, Mercurio AM. Metabolic stress induces the lysosomal degradation of neuropilin-1 but not neuropilin-2. J Biol Chem. 2008;283:28074\u201380.","journal-title":"J Biol Chem"},{"key":"1021_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.05.002","volume":"486","author":"Q Xiong","year":"2020","unstructured":"Xiong Q, Liu B, Ding M, Zhou J, Yang C, Chen Y. Hypoxia and cancer related pathology. Cancer Lett. 2020;486:1\u20137.","journal-title":"Cancer Lett"},{"key":"1021_CR52","first-page":"176","volume":"1865","author":"J Vriend","year":"2016","unstructured":"Vriend J, Reiter RJ. Melatonin and the von Hippel-Lindau\/HIF-1 oxygen sensing mechanism: a review. Biochim Biophys Acta. 2016;1865:176\u201383.","journal-title":"Biochim Biophys Acta"},{"key":"1021_CR53","doi-asserted-by":"publisher","first-page":"11121","DOI":"10.18632\/oncotarget.2553","volume":"5","author":"PY Zhuang","year":"2014","unstructured":"Zhuang PY, Wang JD, Tang ZH, Zhou XP, Yang Y, Quan ZW, et al. Peritumoral Neuropilin-1 and VEGF receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy. Oncotarget. 2014;5:11121\u201332.","journal-title":"Oncotarget"},{"key":"1021_CR54","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/mc.22936","volume":"58","author":"XJ Chen","year":"2019","unstructured":"Chen XJ, Wu S, Yan RM, Fan LS, Yu L, Zhang YM, et al. The role of the hypoxia-Nrp-1 axis in the activation of M2-like tumor-associated macrophages in the tumor microenvironment of cervical cancer. Mol Carcinog. 2019;58:388\u201397.","journal-title":"Mol Carcinog"},{"key":"1021_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03682-z","volume":"12","author":"R Fu","year":"2021","unstructured":"Fu R, Du W, Ding Z, Wang Y, Li Y, Zhu J, et al. HIF-1\u03b1 promoted vasculogenic mimicry formation in lung adenocarcinoma through NRP1 upregulation in the hypoxic tumor microenvironment. Cell Death Dis. 2021;12:394.","journal-title":"Cell Death Dis"},{"key":"1021_CR56","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10456-013-9394-1","volume":"17","author":"YY Wu","year":"2014","unstructured":"Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC, Hong TM. MiR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis. 2014;17:247\u201360.","journal-title":"Angiogenesis"},{"key":"1021_CR57","first-page":"594","volume":"76","author":"M Takahashi","year":"2021","unstructured":"Takahashi M, Okada K, Ouch R, Konno T, Usui K, Suzuki H, et al. Fibronectin plays a major role in hypoxia-induced lenvatinib resistance in hepatocellular carcinoma PLC\/PRF\/5 cells. Pharmazie. 2021;76:594\u2013601.","journal-title":"Pharmazie"},{"key":"1021_CR58","doi-asserted-by":"publisher","first-page":"882372","DOI":"10.3389\/fonc.2022.882372","volume":"12","author":"SP Chen","year":"2022","unstructured":"Chen SP, Zhu GQ, Xing XX, Wan JL, Cai JL, Du JX, et al. LncRNA USP2-AS1 promotes hepatocellular carcinoma growth by enhancing YBX1-mediated HIF1\u03b1 protein translation under hypoxia. Front Oncol. 2022;12:882372.","journal-title":"Front Oncol"},{"key":"1021_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccr.2010.02.030","volume":"17","author":"P Mak","year":"2010","unstructured":"Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, et al. ER\u03b2 impedes prostate cancer EMT by destabilizing HIF-1\u03b1 and inhibiting VEGF-mediated Snail nuclear localization: implications for Gleason Grading. Cancer Cell. 2010;17:319\u201332.","journal-title":"Cancer Cell"},{"key":"1021_CR60","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jhep.2016.04.019","volume":"65","author":"FQ Wu","year":"2016","unstructured":"Wu FQ, Fang T, Yu LX, Lv GS, Lv HW, Liang D, et al. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1\u03b1. J Hepatol. 2016;65:314\u201324.","journal-title":"J Hepatol"},{"key":"1021_CR61","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/jcp.26855","volume":"234","author":"MA Rodr\u00edguez-Hern\u00e1ndez","year":"2018","unstructured":"Rodr\u00edguez-Hern\u00e1ndez MA, Gonz\u00e1lez R, de la Rosa \u00c1J, Gallego P, Ord\u00f3\u00f1ez R, Navarro-Villar\u00e1n E, et al. Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells. J Cell Physiol. 2018;234:692\u2013708.","journal-title":"J Cell Physiol"},{"key":"1021_CR62","first-page":"1805","volume":"39","author":"S Owada","year":"2018","unstructured":"Owada S, Endo H, Shida Y, Okada C, Ito K, Nezu T, et al. Autophagy-mediated adaptation of hepatocellular carcinoma cells to hypoxia-mimicking conditions constitutes an attractive therapeutic target. Oncol Rep. 2018;39:1805\u201312.","journal-title":"Oncol Rep"},{"key":"1021_CR63","doi-asserted-by":"publisher","first-page":"e103181","DOI":"10.15252\/embj.2019103181","volume":"39","author":"Z Lin","year":"2020","unstructured":"Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, et al. RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3\u2010mediated autophagy. EMBO J. 2020;39:e103181.","journal-title":"EMBO J"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01021-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T02:59:47Z","timestamp":1728356387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01021-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1038\/s41401-022-01021-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"21 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}